

d1
cont

317. A method of treating a human cancer comprising administering to a human in need of such treatment an amount of Newcastle disease virus effective for treating said cancer, which alone is cytolytic for said cancer, using a route of administration selected from the group consisting of intraperitoneal, endoscopic, oral and topical administration.

REMARKS

Reconsideration and allowance of the above-identified application is respectfully requested.

The claims have been rewritten to more distinctly claim the subject invention. All claims are directed to a method of treating cancer or a method of reducing the size of a tumor. Support for the claims can be found on pages 11-15 and throughout the specification. Support for the phrase "of moderate virulence" in claim 308 can be found at page 6 (figure 5 legend).

Claims 141-143, 164, 165, 167, 168 and 177 stand rejected under 35 U.S.C. §112 first paragraph. Applicants submit that this rejection is obviated in view of the new claims.

Robert M. LORENCE et al
Serial No. 08/260,536

Claims 141-143, 164, 165, 167, 168 and 177 stand rejected under: 35 U.S.C. §102(b) as being anticipated by Lorence et al; rejected under 35 U.S.C. §102(a) as being anticipated by Reichard et al; and rejected under 35 U.S.C. §102(b) as being anticipated by Reichard et al. Applicants submit that these rejections are obviated in view of the new claims.

Should any small matters remain outstanding, Examiner Scheiner is encouraged to telephone Applicants' undersigned attorney at 816-4021 so that same can be resolved without the necessity of an additional action and response thereto.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: 

Thomas E. Byrne
Reg. No. 32,205

TEB:lmo
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100